Assetmark, Inc Legend Biotech Corp Transaction History

Assetmark, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	SELL	$63.16 - $76.5 $3,347 - $4,054	-53 Reduced 74.65%	18 $1,000
Q2 2023 Aug 11, 2023	SELL	$46.28 - $75.01 $694 - $1,125	-15 Reduced 17.44%	71 $4,000
Q1 2023 May 05, 2023	BUY	$43.42 - $57.37 $564 - $745	13 Added 17.81%	86 $4,000
Q4 2022 Feb 10, 2023	SELL	$38.8 - $55.46 $698 - $998	-18 Reduced 19.78%	73 $3,000
Q3 2022 Nov 01, 2022	SELL	$38.15 - $57.1 $190 - $285	-5 Reduced 5.21%	91 $4,000
Q1 2022 May 13, 2022	BUY	$31.02 - $48.18 $2,977 - $4,625	96 New	96 $3,000

205

74.5M

371K

387K

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $6.7B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.